Table 2 Best tumor response based on mRECIST and RECIST after the first DTACE between the two groups

From: Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial

 

mRECIST, n (%)

 

RECIST 1.1, n (%)

 
 

DEB-TACE (n = 121)

DEB-TACE + apatinib (n = 122)

P value

DEB-TACE (n = 121)

DEB-TACE + apatinib (n = 122)

P value

Tumor response

 CR

9 (7.4)

14 (11.5)

0.036

0

0

0.066

 PR

38 (30.4)

55 (45.1)

39 (32.2)

54 (44.3)

 SD

50 (41.3)

40 (32.8)

56 (46.3)

53 (43.4)

 PD

24 (19.8)

13 (10.7)

26 (21.5)

15 (12.3)

ORR (CR + PR)

47 (38.8)

69 (56.6)

0.006

39 (32.3)

54 (44.3)

0.054

DCR (CR + PR + SD)

97 (80.2)

109 (89.3)

0.046

95 (78.5)

107 (87.7)

0.056

  1. RECIST Response Evaluation Criteria in Solid Tumors, mRECIST modified RECIST, DEB-TACE drug-eluting beads transarterial chemoembolization, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate
Back to article page